OncoMatch/Clinical Trials/NCT05167994
Preoperative IMRT With Concurrent Anlotinib for Localised Extremity or Trunk Sarcoma （SPARE-01）
Is NCT05167994 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Anlotinib hydrochloride for sarcoma,soft tissue.
Treatment: Anlotinib hydrochloride — To investigate the safety and efficacy of preoperative IMRT and concurrent Anlotinib Hydrochloride for primary truncal or extremity soft tissue sarcoma; To investigate the Quality of life and extremity function post-combination treatment; To study the mechanism of radio-sensitizing effects of Anlotinib Hydrochloride for primary truncal or extremity soft tissue sarcoma; To assess the relationship between the MRI imaging, pathological findings and local control.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Sarcoma
Performance status
ECOG 0–3(Limited self-care)
Prior therapy
Cannot have received: radiation therapy
Cannot have received: neoadjuvant chemotherapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05167994 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radiation therapy, neoadjuvant chemotherapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages